An application of Bacteriocin-Producing Vaginal Lactobacillus Crispatus IS30 in A Gel Formula Against Some Vaginal Pathogens

The aim of this study was to evaluate the possibility using Lactobacillus cells as a probiotic treat some vaginal infections. For purpose, thirty isolates were collected from samples subjected screening program investigate their antagonism abilities against four vaginosis species: Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumonia and Proteus spp. Eighteen selected primary (agar plug diffusion method) based on ability inhibit growth 4 indicators which then secondary with two methods: detection bacteriocin activity biofilm forming capacity. isolate IS30 its high production well being producer. Further identification tests revealed that crispatus. Optimization experiments MRS broth best medium for biomass glucose yeast extract carbon nitrogen sources. maximum observed in optimized culture 15.9 mg/mL 40 AU/mL respectively, hence used preparation formula containing cells. Study properties demonstrated capability crispatus tolerate acidity an adhere epithelial Moreover, showed auto-aggregation (72.66%) 58% co-aggregation percentage after 5 hours. successfully incorporated into gel bases results have kept viability over 14 days produce releasing bacteriocin. tested P. aeruginosa E. coli confirmed both species.